Biotechnology pioneer Genflow Biosciences has officially announced that its landmark Phase 2 clinical trial, SLAB (Sarcopenia and Longevity in Aged Beagles), successfully met its primary safety and primary efficacy endpoints. The positive readout marks a major leap forward in companion animal longevity and veterinary therapeutics.
Targeted SIRT6 Gene Therapy Reverses Biomarkers of Aging
The SLAB trial evaluated Genflow’s proprietary SIRT6 “centenarian” gene therapy, a treatment designed to introduce a high-activity variant of the SIRT6 gene derived from human centenarians. The therapy directly addresses sarcopenia—the age-related loss of skeletal muscle mass and strength—alongside broader cellular degradation in aging companion animals.
Key Trial Takeaways
-
Safety Profile: The gene therapy demonstrated exceptional tolerability across aged canine cohorts, with no treatment-related adverse events reported.
-
Efficacy & Epigenetics: Treated animals demonstrated clear improvements in biological age metrics, validated using the GRIM methylation clock alongside muscle function assessments.
-
Mode of Action: By bolstering cellular DNA repair and metabolic regulation, the SIRT6 variant preserves muscle integrity and reduces systemic frailty in geriatric dogs.
Next Steps & Industry Summit Presentation
Full quantitative data, biomarker readouts, and long-term functional tracking from the SLAB trial will be presented in detail at the upcoming Animal Longevity Summit.
The positive readout validates Genflow’s platform technology and sets the foundation for expanding SIRT6 gene therapy applications across both veterinary medicine and translational human longevity pipelines.
